Porton Biopharma Developing and Manufacturing Life-Saving Biopharmaceutical Products

PBL is an experienced developer and manufacturer of life-saving therapeutics.

Porton Biopharma (PBL) is a UK-based company experienced in developing, manufacturing, and bringing life-saving biopharmaceutical therapeutics and vaccines to market.

The company is an expert at taking concepts from the research laboratory to production, progressing through various stages of scale-up and process development. The result is clinical-grade material, which is suitable for clinical trial. This includes both native and recombinant therapeutic proteins.

Manufacturing and product development

Porton Biopharma’s development group offers a range of product-focused services, including development and scale-up, product characterisation, analytical development and qualification, and process troubleshooting, as well as good manufacturing practice (GMP) manufacturing capacity.

Its state-of-the-art current good manufacturing process (cGMP) manufacturing facilities are licensed by the Medicines and Helathcare Products Regulatory Agency (MHRA), Food and Drug Administration (FDA), and Pharmaceuticals and Medical Devices Agency (PMDA).

The facilities are used for its biopharmaceutical products, which include the UK’s licensed anthrax vaccine, and therapeutic enzyme Erwinase®, which is used to treat acute lymphoblastic leukaemia (ALL) and is licensed in 20 territories worldwide.

Specialist expertise focused on delivery

By building on the knowledge and experience gained from successfully manufacturing its own products, the company is able to provide both facilities and expertise to clients for the production of a wide range of clinical materials.

These including unique containment level 3 capabilities geared to the bespoke manufacture of low-volume, high potency and toxicity bacterial products.

PBL also offers access to its specialist laboratories and bespoke services for translational development to help new biopharmaceutical products progress from gene to GMP.

World-wide academic knowledge for greater developmental capabilities

PBL work with both start-up biotech and large pharmaceutical organisations on a worldwide basis and have active collaborations with academic departments engaged in bioprocessing developments.

Several of its staff are visiting university lecturers, which means they are able to offer a broad knowledge of developmental capabilities ranging from the creation of entire biopharmaceutical manufacturing schemes from research scale methodologies to the development of individual process components.

Having developed its own products for many decades and worked with a wide range of customers, PBL has a wealth of experience that can be applied flexibly to aid clients at all stages of development. It takes pride in its high-level of communication, which enables the company to work with its customers and reflect their needs.

Process redevelopment and qualification

Experience gained from the continuous improvement of its processes enables PBL to offer a complete range of services, including complete process redesign, introduction of disposable technology and improved analytical methods. Such activities are underpinned by the expert knowledge of its regulatory and validation teams.

Analytical development and qualification

The company’s development group designs and adapts a wide range of analytical techniques to demonstrate process reproducibility and product quality. Method qualification ensures that such techniques are fit for their intended purpose.

Process troubleshooting

Long-established manufacturing processes may suffer from unexpected problems. PBL’s staff are adept at determining the root cause of process failures outside of the manufacturing environment. This vigilance reduces costs and manufacturing down-time, and also allows them to provide advice on appropriate remedial action.

About Porton Biopharma

Porton Biopharma’s strategy as a new company with a distinguished heritage is to grow its existing business and product pipeline, whilst also building relationships across the industry.

It was commercialised out of Public Health England on 1 April 2015, which enabled it to be better placed to grow the business of developing and manufacturing life-saving products. The company is built upon decades of biopharmaceutical experience, including the successful licensure of many therapies that save thousands of lives every year and generate revenues from world-wide sales.

PBL offers expertise in developmental production of biologicals, including product characterisation, process and analytical validation, and scalability for market. Allied with its experience of regulatory compliance gained from the licensure of its own products, this puts it in an ideal position to offer expertise and enable others to successfully bring their products to market.

In order to find out how Porton Biopharma can help you move your research from the bench to the clinic, please contact them via the enquiry box.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Opening of the Pharm-Stores Extension Demonstrates Investment in Porton Biopharma

Chairman of the Porton Biopharma (PBL) Martin Hindle opened an extension of its facility for the storage of raw materials.

White Papers

Porton Biopharma (PBL) Brochure

Porton Biopharma (PBL) manufactures the UK's licensed anthrax vaccine for and on behalf of the UK Government.

Address
Porton Biopharma

Manor Farm Road

Porton Down

Salisbury

SP4 0JG

Wiltshire

United Kingdom

+44 1980 619723 +44 1980 612100 01980 612241 www.portonbiopharma.com

Porton Biopharma Images

Products and Services

Press Release

30 June 2017

UK-based Porton Biopharma Limited (PBL) is pleased to announce it has officially opened and named its new multi-million pound pharmaceutical laboratories.

Read more
19 June 2017

Porton Biopharma Ltd (PBL) has announced that it has signed a modification to its contract with the US National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine. The contract modification is worth US$5.6 million.

Read more
31 March 2017

In a ribbon cutting ceremony Dr Peter Hughes, Director of Quality at Porton Biopharma (PBL) has opened a brand new suite of office accommodation to bring together members of quality assurance (QA) and other departments into one integrated set of buildings.

Read more
27 June 2016

In a ceremony led by Baroness Scott of Bybrook OBE, Porton Biopharma (PBL) has begun construction of a new pharmaceutical development facility, which will provide state-of-the-art facilities for its teams of scientists.

Read more
16 May 2016

In a ceremony led by Salisbury's MP John Glen, Porton Biopharma has initiated construction of a new multi-million facility.

Read more
9 May 2016

Chairman of the Porton Biopharma (PBL) Martin Hindle opened an extension of its facility for the storage of raw materials.

Read more
9 May 2016

Ohara Pharmaceutical have submitted a new drug application for PBL's Erwinase® in Japan.

Read more
9 May 2016

A new mutli-million pharmaceutical manufacturing facility has been opened at Porton Biopharma (PBL).

Read more
2 July 2015

The transfer of Public Health England's (PHE) clinical drug development and production capability into a standalone, state-owned biopharmaceutical limited company has been approved by the Secretary of State for Health.

Read more
29 April 2010

Digimarc Corporation, a leading supplier of digital watermarking technologies and solutions, and AlpVision, an emerging leader in brand protection and anti-counterfeiting solutions headquartered in Switzerland, are joining forces with a worldwide strategic licence agreement. The agreement enables

Read more
19 April 2006

With the new Indumax H CLS54, Endress+Hauser is launching a conductivity sensor with certified hygienic design onto the market. It is specially designed for the pharmaceutical and biotechnology sectors, where proof of hygiene in the form of the relevant certificates is indispensable. <

Read more
3 March 2006

In the very first steps, you decide how the project will be structured, depending on your own resources, timeline and cost situation. Will you integrate small units? Bundle packages? Cooperate with a general engineering company? Go for a turnkey project? The costs for measurement instru

Read more
7 October 2005

Endress+Hauser's new loop-powered Liquiline M for pH or conductivity measurement is so easy to use! It features a large plain text display showing the measured value in figures 28mm high for easy reading and with step by step menu-driven operation, user error is virtually eliminated.

Read more
5 April 2005

For a long time, Endress+Hauser has been the worldwide leader for delivering digital Profibus process measuring instruments. This was an absolute must to get the knowledge and ability to provide not only the instruments but also the relevant documentation, according to the GxP’s guid

Read more
5 April 2005

The first basic GxP principle says: “the partners of the GxP manufacturers have also to be compliant". This is the reason why Endress+Hauser implements compliant activities in different facilities (Product Centers and Sales Centers). A corporate Validation Master Plan wi

Read more
23 March 2005

The role of instrumentation from Endress+Hauser. Conductivity measurement in the CIP system plays a key role in managing the waste of cleaning products and maintaining the quality of the cleaning agent to obtain maximum cleanability. Conductivity is used in two different applications on the

Read more
2 December 2003

2nd December 2003 - FlexLink is pleased to offer a new generation of the PCB handling platform providing high quality, reliable solutions for a wide range of handling requirements. All modules have ESD safe designs and are CE marked. The complete product range utilizes a

Read more
2 December 2003

New massflow FRS technology 2nd December 2003 - FlexLink is proud to launch the very latest in FIFO reservoir systems (FRS) development from our Secondary Technology Unit. The new FlexLink FRS technology is designed to maximize process and operator efficiency. HMI software c

Read more

Regional Offices

Porton Biopharma

Manor Farm Road

Porton Down

Salisbury

SP4 0JG

Wiltshire

United Kingdom

+44 1980 619723 +44 1980 612100 01980 612241 www.portonbiopharma.com

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.